KR20230070787A - A pharmaceutical composition for use of treating neuropathic pain comprising sogunjungtang and a method of preparing the composition - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for treating neuropathic pain comprising Sogeonjungtang and a method for preparing the same.

Description

A pharmaceutical composition for use of treating neuropathic pain comprising sogunjungtang and a method of preparing the composition}

The present invention relates to a pharmaceutical composition for treating neuropathic pain comprising Sogeonjungtang and a method for preparing the same.

According to the definition of the International Association for the Study of Pain (IASP), neuropathic pain is pain initiated or caused by a primary lesion or dysfunction of the nervous system. lesion or dysfunction in the nerve system). Pain caused by damage to the nervous system or functional abnormality, which is usually intractable and chronic, causes patients to suffer from a markedly reduced quality of life, resulting in not only the pain itself but also sleep disorders, emotional disorders such as depression, and reduced productivity due to reduced social adaptability. It is a pain syndrome that causes social problems.

Clinically, various symptoms may appear, and allodynia, hyperalgesia, and spontaneous pain are characteristically observed. In general, the transmission of sensory signals from the damaged area is out of the norm, and pain is felt even in weak stimuli that do not feel pain under normal conditions. It is called allodynia. Hyperalgesia, abnormal sensation, which is a spontaneous and intermittent painless abnormal sensation, and paresthesia, which is an unpleasant sensation that is spontaneous or induced, are called spontaneous pain.

Neuropathic pain inhibitors include nonsteroidal anti-inflammatory drugs (NSAIDs); anticonvulsants such as gabapentin and pregabalin that act on calcium channels; anticonvulsants such as carbamazepine that act on sodium channels; Serotonin Norepinephrine Reuptake Inhibitor (SNRI) antidepressants; and opioids, which are recommended only for emergencies, are used clinically. Non-steroidal anti-inflammatory drugs are not effective in relieving pain, and most anti-pain drugs are used in combination, but all drugs in each class have similar side effects. However, there is a problem that the therapeutic effect is low.

Since neuropathic pain inhibitors are usually administered to patients for a long period of time, the most ideal preventive and therapeutic agents for neuropathic pain should be low-toxic and orally administrable. In addition, it has been reported that 75% of neuropathic pain patients still experience severe pain despite the development of various analgesics or analgesic methods to date. As such, it is an effective treatment or inhibitor for neuropathic pain, free from toxicity and side effects, and has more analgesic effect. It is required to develop a pain suppressor, treatment, or food with a high value.

Korean Patent Application No. 10-2020-0020890 Korean Patent Application No. 10-2020-0001142

doesn't exist

Accordingly, an object of the present invention is to provide a drug capable of effectively suppressing neuropathic pain while being safe for long-term administration with little toxicity or side effects.

One aspect of the present invention relates to a pharmaceutical composition for treating neuropathic pain, including Sogeonjungtang.

Another aspect of the present invention is to prepare a sogeonjungtang by extracting peony, licorice, gyeji, health, and jujube in an extraction solvent, and adding a pharmaceutically acceptable carrier, excipient and / or diluent to the sogeonjungtang, It relates to a method for preparing a pharmaceutical composition for treating neuropathic pain, including preparing the pharmaceutical composition.

The composition of one aspect of the present invention is a preparation that can be used even for infants under 1 year of age, and has no side effects such as drowsiness, dizziness, weight gain, and risk of suicidal ideation even when administered for a long period of time, and effectively suppresses neuropathic pain. can do.

The composition of one aspect of the present invention has an effect of restoring damaged nerves, and can be used without side effects in the early stage of pain, thereby improving the quality of life of patients.

Figure 1 shows a portion of the foot of a rat to which the filament strength increase for the Von Frey test of an embodiment of the present invention is applied.
2 is a graph showing test results in the Von Frey test when a composition of one embodiment of the present invention is administered to a neuropathic pain animal model (CCI).
Figure 3 is a graph showing test results in the Rotarod test, which is a behavioral test when the composition of one embodiment of the present invention is administered to a neuropathic pain animal model (CCI).
Figure 4 is a graph showing the results of measuring the TNF-α concentration at 1, 2 and 3 weeks after administration of the composition of one aspect of the present invention to a neuropathic pain animal model (CCI).

One aspect of the present invention relates to a pharmaceutical composition for treating neuropathic pain, including Sogeonjungtang.

Sogeonjungtang is a herbal medicine prescribed in Sanghanron, Geumgweyoryak, and Donguibogam. Currently, the efficacy and effects approved for Sogeonjungtang are 'easy to get tired due to constitutional weakness, poor complexion, abdominal pain, palpitations, hot or cold hands and feet, frequent urination or polyuria, etc. Symptoms accompanying: weak constitution in children, fatigue boredom , nervousness, chronic gastroenteritis, childhood enuresis, and night enuresis'.

내지 120

의 온도에서, 30분 내지 12시간 동안 추출 용매로 추출될 수 있다. 상기 추출 용매는 물 또는 에탄올일 수 있다.Sogeonjungtang is an extract of peony, licorice, cinnamon, health, and jujube, and contains additional gyogi. In an embodiment, Sogeonjungtang is a hot water extract of peony, licorice, gyeji, health, and jujube. The extract was 80

to 120

At a temperature of, it can be extracted with an extraction solvent for 30 minutes to 12 hours. The extraction solvent may be water or ethanol.

The oriental medicine efficacy and pharmacological analysis of herbal medicines composed of Sogeonjungtang described in Herbology are as follows:

- Peony (芍藥): clear heat and blood, goose ache (祛瘀止痛), yang blood and yin (養血斂陰). Used for pain treatment for peaceful liver yang and lactation

- Gyeji: sweating, blood circulation

- Jujube (大棗): It is a basic herbal medicine for decoction, and there is no record of specific efficacy alone.

- Licorice (甘草): Reduces pain and detoxification by clearing and detoxifying heat

-Health (乾薑): On-jung (溫中), Hoi-yang (回-陽), On-lung harmony (溫肺化飮), On-kyung hemostasis (溫經止血)

- Gyoi (膠飴): Efficient for upper extremity, second-grade abdominal pain, lung algae, hematemesis, dry mouth, sore throat, and constipation.

Furthermore, the main ingredients and pharmacological actions of the herbal medicines composed of Sogeonjungtang that have been identified so far are as follows:

herbal medicine Ingredients main ingredient efficacy note peony monoterpenes albiflorin calm, serenity Indicator substance peony monoterpenes paeoniflorin calm, serenity Indicator substance peony monoterpenes oxypaeoinflorin anti-inflammatory, antioxidant peony monoterpenes benzoylpaeoniflorin anti-allergy licorice saponins glycyrrhizin anti-inflammatory, blood circulation Indicator substance licorice triterpenes glycyrrhetic acid anti-inflammatory, anti-cancer licorice flavonoids liquiritin anti-inflammatory, cell protection licorice isoflavonoids formononetin Osteoporosis inhibition, antioxidant licorice chalcone isoliquiritin antioxidant, cell protection gyeji phenylpropanoids cinnamic acid anti-inflammatory, dry stomach Indicator substance gyeji phenylpropanoids cinnamaldehyde blood circulation, anticancer gyeji phenylpropanoids cinnamyl acetate health gyeji tannin epicatechin antiviral health etc 6-gingerol sweating, pain health etc 4-shogaol health health etc zingerone antibacterial health sesquiterpenes zingiberene gastric ulcer health sesquiterpenes β-bisabolene antibacterial jujube saponins jujuboside A Calm jujube saponins jujuboside B soothing, blood circulation jujube terpenoid jujuboside C soothing, blood circulation jujube phenolic zizibeoside I soothing, blood circulation jujube etc vomifoliol soothing, blood circulation Kyoi sugars maltose replenish energy

As described above, among the known effects of Sogeonjungtang, there was no therapeutic effect on neuropathic pain, but the present inventors accidentally discovered that Sogeonjungtang was effective for neuropathic pain.

The pharmaceutical composition according to the present invention is characterized in that it is used for preventing or treating neuropathic pain. In the present invention, neuropathic pain refers to peripheral neuropathic or central neuropathic pain, and peripheral neuropathic pain refers to postherpetic neuralgia, trigeminal neuralgia, postoperative pain, human immunodeficiency virus, cancer, peripheral nerve damage, spinal canal pain after stenosis or herniated disc, or diabetic neuralgia, and the like, and central neuropathic pain may be pain caused by cancer, multiple sclerosis, stroke, cerebral infarction, or spinal cord injury. Symptoms of neuropathic pain that can be treated or prevented or alleviated by the compositions according to the present invention can, in embodiments, be one or more pain consisting of spontaneous pain, hypoesthesia, paresthesia, unpleasant sensation, allodynia, and hyperalgesia.

Diagnosis of neuropathic pain is made using clinical assessment tools rather than diagnostic imaging or biochemical tests. PD-Q( PainDETECT questionnaire). For the PD-Q questions to directly evaluate neuropathic pain, the patient evaluates symptoms such as stabbing pain and feeling like ants are crawling, and if the total score is 12 points or less, the possibility of neuropathic pain is low, A score of 19 or higher can be diagnosed as a high possibility of neuropathic pain. The composition of the present invention can be used for patients with neuropathic pain whose total pain score according to the PD-Q score is 13 points or more, specifically 18 points or more, or 20 points or more.

The pharmaceutical composition according to the present invention may be administered individually or in combination with other types of neuropathic pain inhibitors. Drugs that can be used together include NSAID agents; analgesics such as Gabapentin and Pregabalin; anticonvulsants such as carbamazepine that act on sodium channels; and SNRI (Serotonin Norepinephrine Reuptake Inhibitor) series antidepressants and the like, but is not limited thereto.

The pharmaceutical composition of the present invention may include Sogeonjungtang, more specifically peony, licorice, gyeji, jujube, health and gyoi at 0.1 to 60% by weight, specifically 5 to 50% by weight. Based on the total weight of peony, licorice, cinnamon, health, jujube and gyoi, Sogeonjungtang contains 5 to 25 wt% of peony, 2 to 15 wt% of licorice, and 4 to 18 wt% of cinnamon. , 4% to 18% jujube, 1% to 6% health, and 30% to 70% gyoza.

Appropriate carriers, excipients and/or diluents commonly used in the preparation of pharmaceutical compositions may further be included. Carriers, excipients and/or diluents that may be included in the pharmaceutical composition include fructose, high fructose, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, and calcium. Phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, sodium L-glutamate monohydrate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. Such formulations may be oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols. When formulated, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants common in the art.

Solid preparations for oral administration include syrups, tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient such as dextrin, starch, calcium carbonate, etc. carbonate), sucrose, lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral administration include suspensions, internal solutions, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. can

A preferred daily dosage of the pharmaceutical composition of the present invention containing at least one of the pharmaceutically acceptable salts and mixtures thereof of the above compounds as an active ingredient is the condition and weight of the patient, the degree of disease, the form of the drug, and the route of administration. And it should be determined in light of various related factors such as duration and severity of disease, and may be appropriately selected by those skilled in the art. However, in order to achieve a desirable neuropathic pain inhibitory effect, the pharmaceutical composition of the present invention is administered in the range of 1 to 3,000 mg/kg body weight, specifically 10 to 2,000 mg/kg body weight, 500 to 1600 mg of Sogeonjungtang per day. It can be administered in the range of /kg body weight. Administration can be administered once a day or divided into several times.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, and the like.

Another aspect of the present invention is to prepare a sogeonjungtang by extracting peony, licorice, cinnamon, health, and jujube, and adding a pharmaceutically acceptable carrier, excipient and / or diluent to the sogeonjungtang, It relates to a method for preparing a pharmaceutical composition for treating neuropathic pain.

The method weighs each of the raw materials of cinnamon, jujube, peony, licorice, and health, adds 8 to 12 times the weight of the extraction solvent based on their weight, and extracts at 80 ° C to 120 ° C for 30 minutes to 12 hours, After filtration, concentration under reduced pressure at 60 ° C. or less may include preparing a soft crude extract. The extraction solvent may be ethanol or water, specifically purified water. In embodiments, the extraction may include adding 8 to 10 times the weight of an extraction solvent based on the weight of each raw material and extracting at 80 ° C to 100 ° C for 1 hour to 6 hours.

Thereafter, a pharmaceutical composition is prepared by adding a mixture and appropriate carriers, excipients and/or diluents to the prepared extract. Suitable carriers, excipients and/or diluents are as described above.

Hereinafter, the present invention will be described in more detail by examples and experimental examples. However, the following examples and experimental examples are only for exemplifying the present invention, and the scope of the present invention is not limited only to these.

Example

1. Preparation of materials

As a composition containing Sogeonjungtang, Kiddy Yeonjo Extract (Samik Pharmaceutical Co., Ltd.: 1 pack (7.5 grams), containing 500mg of peony, 250mg of licorice, 330mg of gyeji, 110mg of health, 330mg of jujube, and 1670mg of gyogi) was used.

Pregabalin was used as a positive control material and sterile water for injection was used as a negative control material.

2. Analgesic effect in rat sciatic nerve ligation-induced neuropathic pain model

A neuropathic constriction injury (CCI) model was created by loosely tying the hindlimb sciatic nerve of rats (total of 48 rats, male) with four sutures and inducing sciatic nerve contraction by ligation.

The animal model was randomly allocated (G2 to G5) into 4 groups. Normal rats for which the CCI model was not created were designated as G1 (12 animals in total). The G3 group below is a group to confirm the establishment of a CCI model with the maximum adult clinical dose of pregabalin.

army gender number of animals animal number dose amount
(mL/kg)
(oral) administration substance army gender number of animals Cohort 1
(1st week autopsy) Cohort 2
(3rd week autopsy) dose amount
(mL/kg) administration substance G1 M 12 1-5 6-12 10 sterile water for injection G2 M 12 13-17 18-24 10 sterile water for injection G3 M 12 25-29 30-36 10 Pregabalin (60 mg/kg) G4 M 12 37-41 42-48 9.23 Sogeonjungtang Composition: Kiddy Yeonjo Extract (usual clinical dose for adults) G5 M 12 49-53 54-60 18.51 Sogeonjungtang Composition: Kiddy Yeonjo Extract (double the dose of G4 group)

(One) Von Frey test

Each test substance was orally administered from the 6th day after the hind limb sciatic nerve ligation was performed. At 1 week, 2 weeks and 3 weeks from the administration date, rats in cohort 2 were subjected to the von Frey test by the method described below:

The rats were placed in a cage (7 cm X 9 cm X 7 cm) with a mesh bottom and evaluated by stimulating the soles of the feet. They were allowed to acclimate to the cage for about 10 minutes or more. The filament intensity was gradually increased to 1, 1.4, 2, 4, 6, 8, 10, 15, 26, and 60 g on the plantar part of the operated leg corresponding to the red dot in Fig. 1, and the stimulation was given 5 times each. The number of occurrences of this is indicated. An avoidance response by stimulation or a paw licking response was observed. The intensity of response at least 3 times out of a total of 5 stimuli was recorded, and the data was expressed as paw withdrawal threshold (PWT, g). After one rat was finished, the same method was performed on the next rat.

(2) Rota rod test

In addition, the Rota-rod test was performed on the animals in cohort 2 at 1, 2 and 3 weeks after the start of administration by the following method:

Rota rod was measured under the condition of increasing 0-20 rpm for 5 minutes, and training was performed three times the day before the measurement. The rat was placed on the rota rod device and the time it took to fall from the device was measured. The above result was expressed as latency to fall (sec).

(3) Measurement of TNF-α concentration

TNF-α concentrations were measured in the rats at 1, 2, and 3 weeks after the start of administration.

(4) Experiment result

As a result of the Von Frey test, which is a behavioral test in the disease animal model (CCI), the behavioral patterns were improved at 2 and 3 weeks after administration of the composition (FIG. 2). More specifically, the Sogeonjungtang-administered group had a statistically significant increase in foot withdrawal threshold (g) compared to the vehicle-administered group at 2 weeks and 3 weeks, and the gastric analgesic effect was greater in the double-dose administration group (G4

In addition, as a result of the Rotarod test, which is a behavioral test in the disease animal model (CCI), the behavioral aspects were improved at 2 and 3 weeks after administration of the composition, and in particular, the analgesic effect of the G4 group at 2 weeks had statistical significance compared to the G2 group, which is a disease model group ( Fig. 3). The Sogeonjungtang-administered group showed equal or significantly improved maintenance time to the pregabalin-administered group at 2 weeks.

In the TNF-α concentration test, TNF-α was suppressed statistically significantly at 1 week in G3, the pregabalin-administered group, but the concentration rather increased at 3 weeks, which is a side effect due to increased TNF-α during long-term administration of pregabalin. It is speculated that this may be the cause of the trigger. On the other hand, there was no significant difference between the G4 and G5 groups compared to the G1 or G2 groups (see FIG. 4).

3. Case Study of Sogeonjungtang-Containing Composition

In patients with neuropathic pain, including post herpetic neuralgia (PHN), a composition containing Sogeonjungtang (Kiddy Yeonjo Extract (Samik Pharmaceutical Co., Ltd.): 1 pack (7.5 grams) of peony 500mg, licorice 250mg, gyeji 330 mg, health 110 mg, jujube 330 mg, gyoi 1670 mg)) was conducted to investigate the efficacy and safety of a case group study.

The purpose of this study is to explore the safety and effectiveness of a composition containing Sogeonjungtang for patients with neuropathic pain.

A total of 50 subjects were targeted, and the recruitment criteria were as follows:

(1) Selection Criteria

1. Adult male and female patients aged 18 years or older who understand the purpose of the study and can cooperate

2. Patients with a score of 19 or higher on the PD-Q test

3. NRS score: Those with moderate pain (4~6) or higher

The main complaint symptoms, confirmed medical history, and PD-Q scores of the recruited subjects are shown in Table 3 below:

[Table 3]

The PD-Q test above It is internationally recommended to use the Pain DETECT questionnaire evaluation tool to select neuropathic pain among other types of pain (1, 2). The Pain DETECT test tool can evaluate various paresthesia profiles in neuropathic pain (3). In the PainDETECT questionnaire, a score of 12 or less indicates a low possibility of neuropathic pain, and a score of 19 or more indicates a high possibility of neuropathic pain (4)

The composition containing Sogeonjungtang was to be taken 4 packets at a time, 3 times a day before or between meals for 6 weeks, with or without acupuncture treatment.

The pain numerical rating scale (NRS) was used as the main evaluation index of the efficacy evaluation variable, which evaluates the intensity of the past week using the NRS. In the NRS, the patient selects one number from 0 to 10 that best represents the current level of discomfort (0 being no pain and 10 being the worst discomfort imaginable). Severe pain was also evaluated by NRS.

The results after 1 week and 2 weeks of the above treatment are shown in Tables 4 and 5 below:

[Table 4]

As can be seen from the above results, no adverse drug reaction was observed, and the average pain number scale after 1 week of treatment was 6.56 before treatment, while the pain intensity was alleviated to 5.2. Furthermore, it can be seen that the intensity or frequency of severe pain has decreased. Twenty-two of 50 cases were neuropathic pain patients with NRS 7 or higher in severe state. All of them improved to a moderate level after 3 weeks of treatment.

[Table 5]

In Table 5, the average pain intensity scale before treatment was 6.56, but after 3 weeks of treatment, it was alleviated to 4.76, improving 1.8. When the NRS score improves by 1.74 points or more, pain is clinically evaluated as improved (7). Furthermore, severe pain intensity improved from 8.88 before treatment to 6.66 after 3 weeks of treatment, showing an improvement of more than 2 points in NRS.

From the above results, it can be seen that the composition for treating neuropathic pain comprising Sogeonjungtang according to the present invention relieves neuropathic pain without side effects.

<Reference>

1. Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain 2007;127(3):199-203.

2. Haanpδδ M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152(1):14-27.

3. Baron R, Tφlle TR, Gockel U, et al. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain 2009;146(1-2):34-40.

4. Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22(10):1911-20.

5. Boonstra AM, Stewart RE, Kφke AJ, et al. Cut-Off Points for Mild, Moderate, and Severe Pain on the Numeric Rating Scale for Pain in Patients with Chronic Musculoskeletal Pain: Variability and Influence of Sex and Catastrophizing. Front Psychol 2016;7:1466.

6. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113(1-2):9-19.

7. Farrar JT, Young JP, Jr., LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94(2):149-58.

Claims (14)

A pharmaceutical composition for treating neuropathic pain, comprising Sogeonjungtang. The pharmaceutical composition of claim 1, wherein the sogeonjungtang is an extract of peony, licorice, gyeji, health, and jujube. The pharmaceutical composition according to claim 2, wherein the extract is extracted in the presence of an extraction solvent at a temperature of 80 °C to 120 °C for 30 minutes to 12 hours. 4. The pharmaceutical composition according to claim 3, wherein the solvent is ethanol or water. The pharmaceutical composition according to claim 1 , wherein the neuropathic pain is peripheral neuropathic or central neuropathic pain. The method according to any one of claims 1 to 5, wherein the peripheral neuropathic pain is postherpetic neuralgia, trigeminal neuralgia, postoperative pain, human immunodeficiency virus-induced pain, cancer pain, peripheral nerve injury pain, A pharmaceutical composition that is spinal stenosis pain or herniated disc pain, or diabetic neuralgia. The pharmaceutical composition according to any one of claims 1 to 5, wherein the central neuropathic pain is pain caused by cancer, multiple sclerosis, stroke, cerebral infarction, or spinal cord injury. 6. The pharmaceutical composition according to any one of claims 1 to 5, further comprising one or more pharmaceutically acceptable carriers, excipients or diluents. The method according to any one of claims 1 to 5, wherein the pharmaceutically acceptable carrier, excipient or diluent is fructose, high fructose, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, Starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, L- At least one selected from the group consisting of monosodium glutamate hydrate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, a pharmaceutical composition. The pharmaceutical composition according to any one of claims 1 to 5, wherein the sogeonjungtang is in the range of 0.1% to 60% by weight of the pharmaceutical composition. Sogeonjungtang was prepared by extracting peony, licorice, cinnamon, health, and jujube in an extraction solvent at 80*?*°C? for 30 minutes to 12 hours,
A method for preparing a pharmaceutical composition for treating neuropathic pain, comprising adding a pharmaceutically acceptable carrier, excipient or diluent to the Sogeonjungtang. The method of claim 11, wherein the extraction solvent is 8 to 12 times the weight of the total weight of the peony, licorice, gyeji, health and jujube. The method according to claim 11, wherein the extraction solvent is water or ethanol. The method according to claim 11, wherein gyogi is further added after preparing the sogeonjungtang.

Images